Marisa Wexler, MS, senior science writer —

Abbott has announced promising preliminary results from the PROGRESS trial (NCT02989610) evaluating its Infinity Deep Brain Stimulation (DBS) System for the treatment of Parkinson’s disease. The initial results, detailed in a press release, suggest that the DBS system achieved its primary goal of broadening the “therapeutic window” — the…

Migraines, obsessive-compulsive disorder, and seasonal allergies seem to be associated with Parkinson’s disease and are likely to occur many years before the typical age of diagnosis, a large study has found. Results of the study, “The Parkinson’s phenome—traits associated with Parkinson’s disease in a broadly phenotyped cohort,” were…

Two new studies in mice suggest that caffeine might have protective effects in the brains of Parkinson’s disease patients. The studies, “Chronic Caffeine Treatment Modulates  Disease Progression in a Transgenic Alpha-Synuclein Prion-Like Spreading Mouse Model of Parkinson’s Disease,” and “Chronic Caffeine Treatment Reverses A-Synuclein-Induced…

Parkinson’s patients who have had the disease for a long time, who do not sleep very efficiently, and have higher motor impairment are more likely to experience sleep benefit — the phenomenon in which Parkinson’s patients wake up feeling better before taking medication. The study with that finding, “…

Parkinson’s disease can sometimes mask the symptoms of other neurological disorders, according to a case report. The report, titled “NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease,” documents the case of a 71-year-old woman who was eventually diagnosed with encephalitis, the symptoms…